What a Nightly Scalp Serum Can Actually Prove in Twelve Weeks

K18's new FutureIQ Biomimetic Hair Longevity Serum asks for one thing above all: a nightly habit. The £110 leave-on serum, the brand's first launch outside its original bond-repair mask since it started in 2020, is applied to the scalp each evening and left to work through what K18 calls the body's overnight "rest and recovery cycle," using what it terms MultiVital technology, biomimetic peptides paired with a root-anchoring complex and antioxidant ingredients. That timing is the product's whole premise: a single daily step, repeated for weeks, rather than a wash-day treatment used occasionally.

The evidence for what that repetition produces comes entirely from K18 itself. The brand's own figures claim up to 19,000 more hairs after twelve weeks of use, up to 70% of participants seeing fewer visible greys, and a fully improved scalp barrier in all participants, according to results published on K18's product page. None of this has appeared in a peer-reviewed journal, and K18 has not disclosed how many people took part or the study's full protocol. The reviewer at runwaylive.com flags the 19,000-hair figure as a ceiling rather than a typical outcome, the kind of number a best-case participant produced rather than an average user should expect. For a routine sold on twelve-week consistency, that gap between the headline stat and what any single user's mirror will show over that period matters more than it would for a wash-out-tomorrow product.

There is also a boundary the serum sits close to without crossing. Under the UK's CAP Code, the Advertising Standards Authority requires robust clinical evidence for any claim that a cosmetic reverses hair loss or greying, and language suggesting a product restores a physiological function can tip a product into needing an MHRA medicines licence rather than sitting in cosmetics. K18 pitches FutureIQ as supporting pigmentation in hair that has not yet grown in grey, not undoing colour already lost, and its professional FAQ reportedly states plainly that it is not a substitute for minoxidil and has not been tested on hair loss from medical conditions. That distinction, cosmetic maintenance versus medical reversal, is what keeps a twelve-week nightly ritual honest about what it can actually demonstrate.

K18 is explicit about who that ritual suits: under 30% grey, with minimal to moderate shedding, sold through both salons and direct-to-consumer channels. Outside that window, on someone with established thinning or a head of hair mostly turned, the same nightly step is asking a cosmetic serum to do a job it was never tested for. The bottle itself does not change that. What changes it is whether the person twisting off the cap each night falls inside the 30% line K18 drew before the first patent application went in.